Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2008 Results
Date:1/29/2009

quisition on January 1, 2008. Therefore, 2009 earnings per share guidance of $4.00 to $4.25 will be compared to 2008 pro-forma non-GAAP earnings per share of $3.82.


    2009 Earnings Per Share Expectations:
                                                2009          2008
                                            Expectations    Results   % Growth
                                            ------------    -------   --------

     Earnings (Loss) per share
      (reported)                            $4.00 to $4.25  ($1.89)      NM
     Financial impact of ImClone
      acquisition, including in-process
      research and development and other
      charges                                     -           4.46
     Charges related to Zyprexa
      investigations                              -           1.20
     Asset impairments and restructuring
      charges (included in asset
      impairments, restructuring and other
      special charges)                            -            .30
     Asset impairments (included in cost
      of sales)                                   -            .04
     In-process research and development
      charges associated with SGX acquisition
      and in-licensing transactions with
      BioMS and TransPharma                       -            .10
     Benefit from resolution of IRS audit         -           (.19)
     Pro forma as if the ImClone acquisition
      was completed on January 1, 2008                        (.20)
                                            --------------  -------
     Earnings per share (pro forma
      non-GAAP)                             $4.00 to $4.25   $3.82   5% to 11%

     Additional information:
     Remove dilutive impact of ImClone
      acquisition                             .30 - .35        .20
                                            --------------  -------
     Earnings per share (pro forma
      non-GAAP) (excluding impact of

'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... evidence mounts showing the potential health benefits of probiotics, ... are taking supplements. And the chemical industry is getting ... health effects could deter growth, so the industry is ... according to the cover story in Chemical & ... the American Chemical Society. , Melody M. Bomgardner, a ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Mothers, exposure during pregnancy to a class of air ... problems in their children. PAH are,released to air during ... coal, and other,organic material. , The study is the ... problems among school‐age children and two complementary measures of ...
... 21 (HealthDay News) -- Alzheimer,s disease and other types of ... brain, new research indicates. The findings from MRI brain ... to use MRI to predict the progression of dementias and ... San Francisco (UCSF) researchers said. They found that Alzheimer,s ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay ... treatments, alternative therapies such as acupuncture, acupressure and dietary ... sinusitis, a new pilot study suggests. The authors ... explore the potential of combining Western medicine with Eastern ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... epidemic to the United States and the economic value of ... to a new report. The problem is that estimates ... out only 10 years, while it may take much longer ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay News) ... in people already taking statins such as Lipitor, making ... alternative, a preliminary new study suggests. Two single-dose ... a group with high cholesterol showed that the drug, ...
... led by A. K. Rajasekaran, PhD, Director of the Nemours ... protein involved in cell function and regulation is stopped by ... published online in the American Journal of Physiology - ... is well recognized as a cause of lung cancer and ...
Cached Medicine News:Health News:Prenatal exposure to combustion-related pollutants and anxiety, attention problems in young children 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 3Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 2Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 3Health News:Statin Alternative Looks Promising in Early Trials 2Health News:Statin Alternative Looks Promising in Early Trials 3Health News:Nemours researchers uncover new evidence of cancer-causing agent present in gaseous phase of cigarette smoke 2
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 6 Physicians Interactive (PI), a leading ... today announced a partnership with OPTIMIZERx Corp ... healthcare professionals with SampleMD, a solution that  allows for ... vouchers, prescription co-pay coupons and other support information directly ...
... 6 e-MDs, an industry leader in the ... and practice management (PM) solutions,  congratulates  the Diabetes ... Medicine of Fort Collins, CO, for their recognition ... Excellence recipients.  The Healthcare Information and Management Systems ...
Cached Medicine Technology:Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 2Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... HEp-2000 ANA uses a patented HEp-2 cell ... increase the sensitivity to SS-A/Ro autoantibodies, without ... independent studies have been published worldwide on ... sensitivity to SS-A/Ro autoantibodies when used in ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
Medicine Products: